Authors

A systematic review of metformin treatment in persons at risk for diabetes mellitus

A recent meta-analysis of 31 randomized controlled trials with 4500 participants showed that metformin treatment significantly decreased weight, improved dyslipidemia and insulin resistance, and reduced the incidence of new-onset diabetes by 40%, with beneficial effects maintained over time. Further studies will show whether the metabolic improvements achieved with metformin treatment will ultimately result in a decrease in cardiovascular morbidity and mortality.

Primary Care Physicians Hold Significant Value in Oncology Care

A discussion held at ASCO 2019 highlighted the statistical value associated with primary care collaboration across specialties.

Long-Term Effects of Anti-VEGF Therapy Sustained with Radiation

Study results demonstrate that low-dose proton beam irradiation may enhance and extend the effects of anti-vascular endothelial growth factor (anti-VEGF) therapy for age-related macular degeneration.

Redesign Your Practice's Retirement Plan?

Recognize New Medical Practice Risks

Is Alternative Medicine to Blame for the Death of Steve Jobs?

Although alternative medicine is a good compliment to conventional medical treatment, Steve Jobs' sole reliance on alternative medicine treatment may be the primary factor for his untimely death.

Navigate Through Your Rocky Cash Flow

The Dow Will Probably Hit 50,000 by 2027

To some investors, this might seem unlikely.

Perlara, Harvard, Undiagnosed Diseases Network to Research Neurodevelopmental Disorders

The drug discovery platform company, Perlara, has joined forces with Harvard Medical School and the Undiagnosed Diseases Network to launch PerlQuests for two rare neurodevelopmental disorders, Coffin-Lowry syndrome, caused by a mutation in the RPS6KA3 gene, and GNAO1 encephalopathy.

Why Is the EHR Market So Anemic?

High costs, unreliable vendors, lengthy installation and transition processes, disruptions to workflow, reduced productivity--it's no wonder that so few practices have adopted full-featured EHRs.

San Diego Surfs a New Wave of Culinary Adventure

More than Fish Tacos

Asthma Not Controlled in More than 50% of All Patients

Cable Cost Blues

Spironolactone and hyperkalemia in congestive heart failure

In 1999 Pitt and colleagues published the results of the RALES trial, an important study showing that the addition of a relatively small dose of the aldosterone antagonist spironolactone to a regimen that included angiotensin-converting enzyme (ACE) in­hibitors for patients with severe congestive heart failure (NYHA Class III-IV) had a striking benefit on mortality

Achieving LDL cholesterol goals in elderly patients with ACS

After an acute coronary syndrome (ACS) event, elderly patients are at greater risk of death and nonfatal coronary events compared with younger patients. Despite this, elderly patients continue to receive less evidence-based therapy. Lipidlowering therapy with statins is now routine practice for the secondary prevention of coronary heart disease. Achieving the optional National Cholesterol Expert Panel goal of a low-density lipoprotein cholesterol level of < 70 mg/dL for ACS patients over 70 years of age could prevent nearly 80 deaths or nonfatal coronary events for every 1000 patients treated for 2 years with a number needed to treat of approximately 12.